ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

Urinary incontinence (UI) after radical prostatectomy is a common and distressing complication for men with prostate cancer.

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

Here are the top 5 stories from 2025 about the advancements in prostate, kidney, and bladder cancers.

Focal therapy now helping in the fight against prostate cancer With focal therapy, doctors are now able to destroy cancer cells without damaging the surrounding nerves and tissue. In today’s ...

A Highlands Ranch massage therapist and former high school coach is facing jail time for touching a client inappropriately during a massage. Michael Dillon Duran, 32, was convicted of one count of ...

A 64-year-old long-distance runner, Todd Elworthy was alarmed and confused when his routine prostate specific antigen (PSA) test was elevated in 2023, and a biopsy came back positive for prostate ...

A study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that most of the benefits of androgen deprivation therapy (ADT) for prostate cancer occur within the first ...

A multicenter clinical study in Austria has shown that a new, highly precise ultrasound approach can successfully target and treat early prostate cancer while preserving patients' quality of life.

Study results indicate darolutamide plus ADT significantly improved median rPFS compared with placebo plus ADT in hormone-sensitive prostate cancer, and the risk of radiologic progression or death was ...